Supplemental Figure Legends

SUPPLEMENTAL FIGURE 1. *C. albicans* induces IL-12 and IL-23 expression within infected skin. *A*, *IL-23p19*, *IL-12p35*, and *IL-12/23p40* mRNA expression 24 hours following *C. albicans* skin infection in WT and the various knockout mice, as measured by Q-PCR. Each dot indicates the amount of mRNA transcript as measured by arbitrary units (AU) of a single specimen and horizontal bars denote the mean of scatter plots. * = p < 0.001 versus WT. Data was analyzed using Kruskal-Wallis test and Scheffe's F test. *B*, IL-23p19 staining of skin 4 days following infection with *C. albicans*. Scale bars = 0.025 mm. *C*, Quantification of IL-23p19+ cells in each of the 4 groups of mice shown in *B*. Data are expressed as mean \pm SD. * = p <0.025 versus WT. Bar graphs were analyzed with Kruskal-Wallis test and Scheffe's F test. *D*, F4/80 and IL-23p19 staining of serial sections of WT mice skin 4 days following infection with *C. albicans*. Scale bars = 0.025 mm. Arrows indicate double positive cells.

SUPPLEMENTAL FIGURE 2. Impaired protein production of IL-17A and IL-22 in IL-23 deficient mice. IL-17A, IL-22, and IL-21 protein expression 48 hours following *Candida* skin infection in WT and the various knockout mice as measured by ELISA. Each dot indicates the level of protein (pg mL⁻¹) of a single specimen and horizontal bars denote the mean of scatter plots. * = p < 0.025 versus WT.

SUPPLEMENTAL FIGURE 3. *C. albicans* induces prominent epidermal hyperplasia overlying the infected dermis in *IL-17A^{-/-}*, *IL-22^{-/-}* and WT mice. *A*, H&E staining of mouse skin 4 days following infection with *C. albicans*. Scale bars = 0.05 mm. *B*, Quantification of

epidermal hyperplasia in each of the 4 groups of mice shown above. Data are expressed as mean epidermal thickness (μ m) ± SD. There were no statistical differences among the groups of mice.

SUPPLEMENTAL FIGURE 4. *A*, IL-17A, IL-22, and IL-21 protein expression 48 hours following *Candida* skin infection in WT and the various knockout mice as measured by ELISA. Each dot indicates single specimen and horizontal bars denote the mean of scatter plots. * = p < 0.025 versus WT. Data was analyzed using Kruskal-Wallis test and Scheffe's F test. *B*, Anti-IL-17A, anti-IL-22 Ab-stained sections of skin 4 days following infection with *C. albicans*. Scale bars = 0.025 mm. *C*, Quantification of IL-17A+ and IL-22+ cells in each of the 3 groups of mice shown in *B*. * = p < 0.025, ** = p < 0.001. Bar graphs were analyzed using Kruskal-Wallis test and Scheffe's F test.





Supplemental Figure 2





Supplemental Figure 3





С



Supplemental Figure 4

| | Blocking | Primary Ab | Secondary Ab |
|----------|--------------------------|---------------------------|-----------------------------|
| IL-17A | 10% goat serum in PBS | Santa Cruz #SC-7927, | Vector Laboratories #BA- |
| | | rabbit anti-IL-17, 1:400 | 1000, goat anti-rabbit IgG, |
| | | | 1:1000 |
| IL-22 | 10% goat serum in PBS | Capralogics #CI-0144, | Vector Laboratories #BA- |
| | | rabbit anti-IL-22, 1:2000 | 1000, goat anti-rabbit IgG, |
| | | | 1:1000 |
| IL-23p19 | 10% goat serum in PBS | Anaspec #54595, rabbit | Vector Laboratories #BA- |
| | | anti-IL-23, 1:400 | 1000, goat anti-rabbit IgG, |
| | | | 1:1000 |
| CD3 | Vector Laboratories #SP- | Santa Cruz #SC-1127, goat | Vector Laboratories #BA- |
| | 5030 animal-free blocker | anti-CD3e, 1:1000 | 9500, horse anti-goat IgG, |
| | | | 1:2000 |
| F4/80 | 5% goat serum and 0.2% | BioLegend #122602, rat | Vector Laboratories #BA- |
| | BSA in PBS | anti-F4/80, 1:50 | 9400, goat anti-rat IgG, |
| | | | 1:500 |
| Gr-1 | 5% goat serum and 0.2% | BD biosciences #550291, | Vector Laboratories #BA- |
| | BSA in PBS | rat anti-Gr-1, 1:10 | 9400, goat anti-rat IgG, |
| | | | 1:500 |

SUPPLEMENTAL TABLE. Antibodies and conditions used for immunohistochemistry.